Chairman of the Board
Mr. Spafford is a founding investor of Great Basin and has served as Chairman of our Board of Directors since its inception. Mr. Spafford was a co-founder, director and senior executive officer of Megahertz Corporation. Megahertz Corporation completed an initial public offering in 1993 and was acquired by U.S. Robotics in 1995 in a transaction valued at approximately $450 million. Since 1994 Mr. Spafford has focused on angel investing and philanthropic work.
Mr. Sam Chawla is a Portfolio Manager at Perceptive Advisors LLC. He is also on the Board of Directors at Response Genetics, Inc.
Prior to joining Perceptive Advisors in August 2013, Mr. Chawla was employed as a Managing Director by UBS Securities LLC, a Director by Credit Suisse Securities (USA) LLC, and a Project Manager by Bloomberg LP.
Mr. Chawla received his undergraduate degree from The Johns Hopkins University and his MBA in Management from Georgetown University - The McDonough School of Business.
Ronald K. Labrum
Mr. Ronald K. Labrum is Independent Director at Great Basin Scientific, Inc., Chairman at Suture Express, Inc., and Independent Director at Wright Medical Group, Inc. He is on the Board of Directors at Great Basin Scientific, Inc., ProCure Treatment Centers, Inc., Aptalis Holdings, Inc., Wright Medical Group, Inc., and Aptalis Pharma, Inc.
Mr. Labrum was previously employed as Chief Executive Officer by Fenwal, Inc., Chief Executive Officer-Healthcare Supply Chain Se by Cardinal Health, Inc., President-Allegiance Manufacturing & Distribution by American Hospital Supply Corp., President by Allegiance Healthcare Corp., and a Principal by Baxter International, Inc.
He received his undergraduate degree from Utah State University.
Mr. Calhoun is a Certified Public Accountant (non-practicing) with a background in auditing and accounting. Mr. Calhoun currently serves on the board and audit committee of Response Genetics, Inc., and Ryerson Holding Corporation. Mr. Calhoun has served previously on the boards and audit committees of five public companies in the pharmaceutical industry up until the dates of their respective sales, including Abraxis Bioscience, Inc., Myogen, Inc., Aspreva Pharmaceuticals Company, Replidyne, Inc. and Adams Respiratory Therapeutics, Inc. Mr. Calhoun also currently serves on the boards of three private companies, including NeuroSigma, Inc., a developer of products that treat major neurological and neuropsychiatric disorders such as epilepsy and depression.
Mr. Calhoun received a B.S. in Accounting from the University of Southern California.
Co-founder and CEO
Mr. Ashton has extensive experience in driving successful marketing, sales, IPO and M&A strategies for advanced-technology companies. His experience includes serving as a senior vice president, sales and marketing at Megahertz—a publicly-held company with annual sales in excess of $150 Million; as a senior officer at Inari, a pre-IPO technology start-up; and as CEO of Printelligent Corporation. Mr. Ashton has a proven track record in successfully managing diverse teams of personnel—scientists, marketing, sales and administrative resources—in high-growth technology companies.